Register Here

2020 Executive Sponsors

Cofactor Genomics
Covance
ERT
Fate Therapeutics
Imaging Endpoints
Invicro
Iovance
IQVIA
NeoGenomics
Parexel
Personalis
Q² Solutions

2020 Associate Sponsors

Biodesix
Cello Health BioConsulting
Medidata
Pieris
PRA Health Sciences
Rgenix
Syneos Health

2020 Showcase Sponsors

ADVAXIS
Axiom Healthcare Strategies
Almac Diagnostic Services
IAG
IntelliStem Technologies

2020 Exhibitors

Caprion
CellGenix
Myriad

2020 Supporting & Educational Partners

Alliance for Regenerative Medicine
Cancer Research Institute CRI
Center for Biotechnology
CIMT
CLSA
Journal of Immunotherapy and Precision Oncology (JIPO)
SITC

2020 Media Partners

Big4Bio
Clinicaltrialvendors
Gene Therapy Net
Life Science Leader
Med Tech Outlook

Overview

IO360˚convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.

The 6th Annual Immuno-Oncology 360° Delivers Three Key Benefits:

  1. Access to KOLs driving the science
  2. Partnership opportunities with all stakeholders in Immuno-Oncology
  3. Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology

Keynotes

Carl H June, MD
Richard W. Vague Professor in Immunotherapy at the Department of Pathology and Laboratory Medicine; Director, Center for Cellular Immunotherapies at the Perelman School of Medicine; Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania

Arie Belldegrun, MD, FACS
Executive Chairman and Co-Founder, Allogene
Andrew Baum COLOR

Andrew Baum, MD
Head of Global Healthcare; Managing Director, Equity Research, Citi

Cornerstone Speaker

Crystal Mackall, MD
Professor of Pediatrics and Medicine; Director, Stanford Center for Cancer Cell Therapy; Director, Parker Institute for Cancer Immunotherapy at Stanford; Associate Director, Stanford Cancer Institute, Stanford University School of Medicine

Strategic Leadership

 

Immuno-Oncology 360° reports on the most current data and rapid advancements to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
  • Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof
  • Partner to expand technology platforms to develop therapeutics at an accelerated rate
  • Receive the latest pre-clinical, translational and clinical data from academia and industry
  • Create and prioritize strategies targeted toward specific tumor types
  • Identify and gain a greater understanding of what assets are available for potential combinations
  • Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
  • Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next
  • Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
  • Obtain coverage on a wide range of emerging technologies

Michel Sadelain

Dr Michel Sadelain, MSKCC delivered the Opening Keynote: CAR T Cell Therapy and the CD19 Paradigm at IO360° 2019.

Dr Laura Esserman, UCSF delivered a keynote on Evolving I-SPY 2 to Optimize Breast Cancer Outcomes at IO360° 2019.

Cancer Veteran Judy Perkins, the 1st person to be declared free of metastatic breast cancer after a course of Immunotherapy joined author Charles Graeber at IO360° 2019 to share her journey.

  

Dr Priti Hegde, Genentech leads a Next Generation Biomarker panel with Dr Dan Chen, IGM Biosciences, Dr Ian McCaffery, Janssen, Dr Alessandra Cesano, NanoString, Dr Theresa LaVallee, Parker Institute and Dr David Messina, Cofactor Genomics at IO360° 2019.

  

If you are interested in participating in the 6th Annual Immuno-Oncology 360° 2020 program, please contact us at service@tcfllc.org. Thank you.

Sincerely,​

kate-bw-3

Kate Woda
Conference Director

 Valerie Bowling New

Valerie Bowling
Executive Director

Meredith Sands
Executive Director, Business Development

 geeta-new-bw

Geeta Bachani
Business Development Manager
elizabeth-bard-bw-2

Elizabeth Bard
Business Development Manager

Bre Bugbee
Marketing Manager

Adam Kolanko
Business Development Manager

 Meg

Meg Gould
Senior Conference Planner

Testimonials

  • "By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there’s quite a lot of folks participating who are not traditionally talking to one another on a daily basis."

    - Roy Baynes, MD, PhD, Merck

  • "I really enjoyed it and connecting with some really interesting and inspiring people with whom I'm sure this is just the beginning of long standing interactions."

    - Jacqueline Karmel, Roche

  • "Thank you again for the amazing invitation, it was truly my pleasure to be able to participate in the excellent event you organized."

    - Christine Ward, BMS

  • "IO360° was one of the best immuno-oncology meetings I’ve been to. Kudos! Great speakers and great dialogue!"

    - Jim Mansfield, PerkinElmer

  • "Congratulations again on the excellent program for the Immuno-Oncology 360° meeting. It was truly well coordinated and the topics were fantastic!"

    - Gilson Baia, PhD, Champions Oncology

  • "Really good, well-rounded and novel content. Congratulations on filling the house beyond capacity and for securing such an impressive speaking faculty."

    - Eileen Daniels, Nektar Therapeutics

  • "Thank you for a great conference!"

    - Elena Spanjaard, Pfizer

  • "Your team did a wonderful job in putting together an interesting and relevant program."

    - Lew Bender, Intensity Therapeutics

  • "It was a great conference and I was happy to be a part of it."

    - Anna Pavlick, DO, MD, NYU Cancer Center